NEW ATAI-Logo_Primary.png
atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change
October 19, 2021 07:00 ET | atai Life Sciences
NEW YORK and BERLIN, Oct. 19, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company, today announced the launch of its new philanthropic...
NEW ATAI-Logo_Primary.png
atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)
October 11, 2021 08:00 ET | atai Life Sciences
NEW YORK, Oct. 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
NEW ATAI-Logo_Primary.png
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder
September 21, 2021 08:00 ET | atai Life Sciences
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid use...
NEW ATAI-Logo_Primary.png
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data
September 15, 2021 08:10 ET | atai Life Sciences
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
NEW ATAI-Logo_Primary.png
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
September 14, 2021 08:00 ET | atai Life Sciences
NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in...
NEW ATAI-Logo_Primary.png
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
September 09, 2021 16:30 ET | atai Life Sciences
BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Participate in Upcoming September Investor Conferences
September 03, 2021 18:00 ET | atai Life Sciences
BERLIN, Sept. 03, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health...
NEW ATAI-Logo_Primary.png
atai Life Sciences legt Finanzergebnisse für das zweite Quartal 2021 und Unternehmens-Update vor
August 17, 2021 15:57 ET | Atai Life Sciences
- Erfolgreicher Nasdaq-Börsengang mit erzieltem Bruttoerlös von 258,8 Millionen US-Dollar, einschließlich Überzuteilung des Unterzeichners - Erhalt von Vorauszahlung von Otsuka in Höhe 20 Millionen...
NEW ATAI-Logo_Primary.png
atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update
August 16, 2021 07:00 ET | atai Life Sciences
-Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters’ over-allotment- -Received $20 million upfront payment from Otsuka as...
NEW ATAI-Logo_Primary.png
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions
August 12, 2021 08:50 ET | atai Life Sciences
BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...